2009-10-26 23:43:02 - Forecast Insight - Epilepsy - Future market upgrade following new drug launches - a new market research report on companiesandmarkets.com

www.companiesandmarkets.com/Summary-Market-Report/forecast-insig ..

Introduction

Driven primarily by continued uptake of UCB´s market leading anticonvulsant, Keppra (levetiracetam), seven major market epilepsy revenues grew strongly at a compound annual growth rate of 11.7% to reach almost $3.8 billion in 2007.

Scope

*This report gives a strategic analysis of the likely impact that recent events will have on the future epilepsy market

*Includes epilepsy-specific sales forecasts for the key brands, generics, and pipeline agents in the seven major markets to 2017

*Provides a global market snapshot by including epilepsy-specific sales analysis for leading brands outside the seven major markets

*Key conclusions are supported by key opinion leader comment

Highlights

Despite the

 

 

failure of UCB´s brivaracetam to meet its primary endpoint in a Phase III trial in Unverricht Lundborg disease, the drug is expected to receive strong uptake in patients with refractory partial-onset seizures. Interviewed key opinion leaders remain optimistic about brivaracetam´s future prospects.

As a result of Valeant´s August 2008 collaboration with GlaxoSmithKline and the release of positive Phase III clinical trial data in September 2008, Datamonitor has upgraded its epilepsy-specific sales forecast for retigabine. However, the drug´s likely three-times daily dosing is not expected to be well received by patients and physicians.

D-Pharm´s DP-VPA (a prodrug of valproic acid), has not made any known progress through clinical development since 2006. As a result, launch of DP-VPA is expected to take place 1 year later than what was estimated in Datamonitor´s previous epilepsy market report and epilepsy-specific sales forecasts for the drug have been downgraded.

Reasons to Purchase

*Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2008 to 2017

*Quantify the current size of the seven major markets and the trends in the rest of the world

*Assess the impact of events, such as patent expiries and new product launches, on the epilepsy-specific sales of key brand name products